- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Bicara Therapeutics Inc. Common Stock(BCAX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BCAX
11/13/2026: BCAX (1-star) is currently NOT-A-BUY. Pass it for now.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibodies for oncology, anchored by its lead candidate ficerafusp alfa. The company's main strengths lie in its innovative scientific platform and targeted approach to hard-to-treat solid tumors like head and neck cancer. Its primary investment growth opportunity centers on upcoming clinical trial readouts and potential expansion into broader oncology indications. However, risks include a lack of commercial revenue, high R&D cash burn, and intense competition from large pharmaceutical incumbents. The stock suits high-risk growth investors willing to monitor clinical milestones and regulatory developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Offers exposure to high-potential clinical-stage oncology innovation and pipeline expansion milestones. |
| Momentum investor | Strong fit while signal remains positive | Stock price is highly reactive to clinical trial catalysts, data readouts, and biotech sector sentiment swings. |
| Value investor | Weak fit | Lacks current revenues, earnings, or traditional valuation metrics due to pre-commercial clinical status. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all cash for clinical development. |
| Low-risk investor | Weak fit | Subject to high binary clinical risks, regulatory uncertainty, and significant equity volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks experience sharp price swings around trial updates and market conditions. |
| Valuation risk | High | Valuation is heavily speculative, anchored on future clinical potential rather than trailing financial metrics. |
| Competition risk (oncology therapeutics) | Medium / high | The company competes with heavily funded pharmaceutical giants dominating the cancer treatment landscape. |
| Business quality | Medium | While backed by a robust scientific platform, the absence of approved commercial products limits current operational maturity. |
| Dividend income | Low / none | No cash returns are distributed to shareholders via dividends. |
| Execution risk | High | Success relies entirely on successfully executing complex clinical trials and securing regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 665.20M USD | Price to earnings Ratio - | 1Y Target Price 32.17 |
Price to earnings Ratio - | 1Y Target Price 32.17 | ||
Volume (30-day avg) 1.8M shares | Beta -0.34 | 52 Weeks Range 7.87 - 30.99 | Updated Date 11/15/2026 |
52 Weeks Range 7.87 - 30.99 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.46 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -39.03% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Product Sales | Currently zero revenue as all therapeutic candidates remain in clinical development. | The company is pre-revenue and depends on future drug approvals or partnerships to generate income. |
| Collaborations and Licensing | Potential upfront fees, milestones, or royalties from strategic pharmaceutical collaborations. | Partnerships can provide non-dilutive funding, though none form a core revenue stream at present. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 223.73M | Price to Sales(TTM) - |
Enterprise Value 223.73M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 66.39M | Shares Floating 37.21M |
Shares Outstanding 66.39M | Shares Floating 37.21M | ||
Percent Insiders 10.23 | Percent Institutions 102.09 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

